Recovery may also be faster with some patients returning to work after several days
Atrial fibrillation has long imposed a quiet, relentless toll on those who carry it — the flutter, the clot risk, the daily medications that trade one burden for another. At Epworth Richmond in Melbourne, a new electrical approach to ablation has compressed a four-hour procedure into one, using precision mapping and pulsed energy rather than heat or cold to silence the heart's misfiring tissue. The shift is not merely technical; for a patient population defined by chronic vigilance, it represents a meaningful reordering of what it means to live with the condition.
- Atrial fibrillation affects hundreds of thousands of Australians, carrying constant stroke risk and demanding lifelong medication regimens that erode quality of life.
- Traditional ablation procedures required up to four hours under anaesthesia, exposing patients to drug risk, slow recovery, and post-procedure discomfort from heat or cold tissue damage.
- Epworth Richmond began using Medtronic's Affera system in February, threading a catheter to the heart and deploying electrical pulses guided by high-definition 3D mapping to destroy abnormal cells with surgical precision.
- Procedure time has dropped to roughly one hour, and early patients like 72-year-old Jennifer Flanagan report leaving hospital pain-free with their heart rhythm restored.
- Cardiologists expect the technology to reduce or eliminate patients' long-term medication needs, lower complication rates, and allow some to return to work within days rather than weeks.
Atrial fibrillation is Australia's most common heart rhythm disorder — a condition in which the heart's upper and lower chambers fall out of sync, leaving patients to live with a racing pulse, the threat of clots, and the ever-present shadow of stroke. For decades, the standard response has been ablation: burning or freezing the rogue tissue responsible for the arrhythmia. Effective, but slow. Patients spent up to four hours under anaesthesia while surgeons worked through the problem cell by cell.
In February, Epworth Richmond in Melbourne began offering a different path. The Affera Cardiac Mapping and Ablation System, developed by Medtronic, replaces heat and cold with pulsed electrical energy. A catheter travels from the leg to the heart, where high-definition 3D mapping guides the procedure with exceptional accuracy. The abnormal cells are eliminated not by burning but by targeted electrical pulses — a mechanism that causes less surrounding damage and, crucially, far less post-procedure pain. What once took an afternoon now takes about an hour.
Dr. Andrei Catanchin, who leads the program, points to the downstream effects: less anaesthesia exposure, faster recovery, and the real possibility that patients can reduce or abandon medications they have taken for years — drugs that carry their own side effects and risks. Jennifer Flanagan, 72, who has managed atrial fibrillation since 2001, underwent the procedure and felt nothing. No soreness, no recovery period marked by discomfort. She left with her rhythm restored.
For those who have spent years monitoring their hearts, swallowing daily pills, and calculating stroke risk, the technology offers something more than a faster procedure. It offers a lighter way of living with the disease — and as it spreads beyond Epworth Richmond, that possibility may reach an ever-growing number of Australians.
Atrial fibrillation is Australia's most common heart rhythm disorder, and it can be deadly. The condition occurs when the upper chambers of the heart lose synchronization with the lower chambers, leaving blood to slosh inefficiently through the body. Patients feel it as a racing pulse, a flutter, a thump—and they live with the constant knowledge that clots can form, that a stroke might be waiting. For decades, the standard treatment has been ablation: burning or freezing the wayward tissue that triggers the arrhythmia. It works, but it takes time. Patients spend up to four hours under anesthesia while surgeons methodically destroy the problem cells.
In February, Epworth Richmond, a private hospital in Melbourne, began using a different approach. The Affera Cardiac Mapping and Ablation System, made by Medtronic, uses pulsed-field energy instead of heat or cold. A catheter is threaded up through the leg to the heart, where high-definition 3D mapping guides the surgeon's hand with extraordinary precision. The abnormal cells are destroyed not by burning but by electrical pulses—a gentler mechanism that leaves less collateral damage in its wake. The result is striking: procedures that once consumed an entire afternoon now take roughly an hour.
Dr. Andrei Catanchin, the cardiologist leading the program, frames the shift in practical terms. Less time under anesthesia means less risk from the drugs themselves. Faster recovery means some patients return to work within days rather than weeks. And because the tissue damage is more selective, more targeted, patients may be able to reduce or eliminate the medications they've been taking for years—drugs that often carry their own burden of side effects. There is also the matter of clot prevention. The gentler approach may lower the risk of thrombosis, one of the most serious complications of atrial fibrillation.
Jennifer Flanagan, 72, has lived with atrial fibrillation since 2001. She underwent the new procedure at Epworth Richmond and noticed something immediately: no pain. The heat-based ablations she might have experienced in the past often left patients sore, uncomfortable in the days that followed. This time, she felt nothing. The pulsed field passed through her tissue and did its work in silence. She walked out of the hospital with her rhythm restored and her body unmarked by the intervention.
For a patient population that has grown accustomed to managing a chronic condition—taking medications daily, monitoring their heart rate, living with the anxiety of potential stroke—this technology represents a genuine upgrade. Faster treatment, less medication, fewer side effects, lower complication rates. The human cost of atrial fibrillation is not just the medical risk; it is the erosion of quality of life, the constant vigilance, the pills that must be swallowed. If pulsed-field ablation can reduce that burden, it changes the calculus of living with the disease. As the technology spreads beyond Epworth Richmond, Australia's growing population of atrial fibrillation patients may find themselves with a path forward that is not just more effective, but genuinely less burdensome.
Citas Notables
This technology is an important upgrade to treat atrial fibrillation. Procedures can take just an hour, compared with up to four hours, which means less time under anaesthesia.— Dr. Andrei Catanchin, heart rhythm specialist cardiologist
The previous treatments used heat which caused some burning and discomfort after, but this time I felt no pain at all.— Jennifer Flanagan, 72-year-old patient
La Conversación del Hearth Otra perspectiva de la historia
Why does the speed of the procedure matter so much? It's still just an hour.
Because you're under general anesthesia. Every minute counts when your body is being chemically suppressed. Four hours is a long time to be vulnerable. One hour is a different conversation.
And the pulsed field—why is that better than just burning the tissue?
Heat ablation works, but it's blunt. You're destroying the bad cells, yes, but you're also scorching everything nearby. Pulsed field is more surgical. It targets the problem and leaves the rest alone. Less inflammation, less pain, less scar tissue forming.
So patients actually feel better afterward?
Jennifer Flanagan felt no pain at all. With the old method, you'd expect soreness for days. That matters when you're 72 and you want to get back to your life.
What about the medications? Why would patients need fewer drugs?
Atrial fibrillation drugs have real side effects—dizziness, fatigue, digestive problems. If the ablation is more complete and causes less damage, the heart is more stable. You don't need as much chemical management.
Is this a cure, or just a better treatment?
It's a better treatment. The arrhythmia can recur. But for many patients, one good ablation with pulsed field might be the only intervention they ever need. That's a different life than taking pills forever.
What happens next? Does every hospital get this technology?
That's the question. It's expensive, it requires training, and it's still new. Right now it's at a private hospital in Melbourne. Whether it spreads depends on cost, evidence, and whether public hospitals can access it.